Q3 Earnings Forecast for XFOR Issued By Brookline Cap M

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities research analysts at Brookline Cap M issued their Q3 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued on Tuesday, March 17th. Brookline Cap M analyst L. Cann anticipates that the company will post earnings of ($0.27) per share for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Cap M also issued estimates for X4 Pharmaceuticals’ Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($0.96) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.85 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its earnings results on Tuesday, March 24th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.14. X4 Pharmaceuticals had a negative return on equity of 115.27% and a negative net margin of 225.55%.The firm had revenue of $2.57 million during the quarter, compared to the consensus estimate of $1.68 million.

XFOR has been the topic of several other reports. Stifel Nicolaus set a $10.00 target price on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Wall Street Zen downgraded shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Zacks Research lowered shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.88.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $4.17 on Friday. The stock’s 50-day moving average is $3.66 and its 200-day moving average is $3.62. X4 Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $9.56. The company has a current ratio of 10.16, a quick ratio of 5.48 and a debt-to-equity ratio of 0.41. The stock has a market cap of $379.14 million, a P/E ratio of -0.96 and a beta of 0.43.

Institutional Trading of X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its holdings in X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the last quarter. Indivisible Partners acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth $40,000. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth $50,000. Two Sigma Investments LP bought a new position in X4 Pharmaceuticals during the third quarter worth $47,000. Finally, Palumbo Wealth Management LLC lifted its holdings in X4 Pharmaceuticals by 18.9% in the fourth quarter. Palumbo Wealth Management LLC now owns 113,357 shares of the company’s stock valued at $453,000 after buying an additional 18,030 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.